Spaulding Clinical Research to Perform Bioequivalence Study for One of World's Largest Pharmaceutical Companies

Published: Sep 13, 2010

WEST BEND, Wis.--(BUSINESS WIRE)--Spaulding Clinical, a Phase 1 Clinical Pharmacology Research Unit and Core ECG Lab announced today that it will serve as the Phase 1 clinical site for an upcoming bioequivalence study for one of the world’s top five pharmaceutical companies.

Back to news